WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Key Highlights
- ➤bioAffinity Technologies (BIAF) targets approximately $4 million gross proceeds
- ➤Registered direct shares priced at $6.122 per share
- ➤Private placement includes warrants for up to 980,072 shares
- ➤Warrants carry a $6.122 exercise price and expire five years after approval
- ➤Net proceeds support CyPath® Lung sales, working capital, and general corporate purposes
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire
JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.
Get started
Create a free account to read the full story.